Aqueous Terminalia arjuna extract modulates expression of key atherosclerosis-related proteins in a hypercholesterolemic rabbit: A proteomic-based study.

Purpose: The present study evaluates the effect of an aqueous extract of Terminalia arjuna (aqTAE) on protein expression in aortic plaques of hypercholesterolemic rabbits using a proteomic approach.

Experimental Design: Thirty male New Zealand rabbits (n = 6) were employed as Gp1 (stock diet); Gp2 (high-fat diet [HFD]); Gp3 (stock diet + aqTAE); Gp4 (HFD + aqTAE); and Gp5 (HFD + atorvastatin) and followed for 6 months. Protein lysates of aortic tissues were separated by 2DE and proteins were identified by MALDI-TOF/MS.

Short-Term Adjuvant Therapy with Terminalia arjuna Attenuates Ongoing Inflammation and Immune Imbalance in Patients with Stable Coronary Artery Disease: In Vitro and In Vivo Evidence.

The present study evaluated the cardioprotective effects of Terminalia arjuna on classical and immuno-inflammatory markers in coronary artery disease (CAD) as an adjuvant therapy. One hundred sixteen patients with stable CAD were administered placebo/T. arjuna (500 mg twice a day) along with medications in a randomized, double-blind clinical trial.

Conventional therapies fail to target inflammation and immune imbalance in subjects with stable coronary artery disease: a system-based approach.

Objective: Cardiovascular diseases are the leading cause of morbidity and mortality. In spite of improved pharmacological interventions, the clinical outcome or response to therapy is poorly linked with the reversal of signs and symptoms of the disease.

Material And Results: Keeping this in view, we evaluated the post-treatment effect of standard therapies on traditional risk factors as well as inflammatory markers in 116 non-diabetic subjects with stable CAD undergoing treatment with conventional drugs for >3 months (Group-II) and 50 normal healthy controls (Group-I).